Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

The objective of this study was to evaluate structural damage progression based on clinical response in rheumatoid arthritis patients with no or limited prior disease-modifying anti-rheumatic drug treatment receiving the Janus kinase (JAK)1/JAK2 inhibitor baricitinib 4 mg, methotrexate (MTX), or the...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Durez, Patrick, Schett, Georg, Naredo, Esperanza, Østergaard, Mikkel, Meszaros, Gabriella, De Leonardis, Francesco, de la Torre, Inmaculada, López-Romero, Pedro, Schlichting, Douglas, Nantz, Eric, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097080/
https://www.ncbi.nlm.nih.gov/pubmed/30078086
http://dx.doi.org/10.1007/s10067-018-4221-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097080/
https://www.ncbi.nlm.nih.gov/pubmed/30078086
http://dx.doi.org/10.1007/s10067-018-4221-0

Ejemplares similares